Neogen Sells Genomics Unit to Zoetis for $160M in Portfolio Streamlining
Event summary
- Neogen to sell its Genomics business (GeneSeek®) to Zoetis for $160M, subject to closing adjustments.
- Transaction expected to close by the end of the first half of Neogen’s 2027 fiscal year.
- Genomics business generated $90M in sales during fiscal year 2025.
- Proceeds to be used primarily for debt reduction.
- Divestiture part of Neogen’s strategy to focus on core food and animal safety markets.
The big picture
Neogen’s sale of its Genomics business to Zoetis aligns with a broader trend of companies streamlining portfolios to focus on core competencies. The $160M deal reflects Zoetis’ strategic interest in expanding its genomic testing capabilities, while Neogen aims to strengthen its balance sheet and concentrate on food safety solutions. This transaction underscores the growing importance of genomic data in animal health and the consolidation within the sector.
What we're watching
- Debt Reduction Impact
- How quickly Neogen can reduce its debt burden with the $160M proceeds and whether this will improve its financial flexibility.
- Strategic Focus
- Whether Neogen can successfully pivot to its core food and animal safety markets without the Genomics business.
- Integration Challenges
- The pace at which Zoetis can integrate the Genomics business and leverage its capabilities within its existing portfolio.
Related topics